Steve serves as chief executive officer at Quantum Exponential and holds directorships at Metcalfe Consultancy Limited and Lifestream. His background includes consulting for Martin Homes and a non-executive role at SimplyPayMe.
Steven is chief executive officer at Quantum Exponential and a company director at Metcalfe Consultancy Limited. He also serves as a non-executive director at Lifestream.
The pre-seed round was led by Science Creates Ventures with backing from a syndicate of institutional and angel investors.
"The UK would massively benefit from delivering major infrastructure projects on time and on budget, and through increased productivity by reducing the time it takes to bring such projects to the point of benefitting people. A big part of this is the difficulty found in mapping the complex unseen environments and hidden critical infrastructure that resides under the ground. Considerable budgets are allocated to ensure that unexpected obstacles can be overcome. On HS2 alone, the contingency for unforeseen ground conditions is £248m."
The funding round saw participation from Quantum Exponential Group and HiJoJo Partners.
"We are committed to providing our shareholders with access to quantum technology companies which are at the forefront of this revolutionary technology. OQC’s achievements, driven by its excellent team, are nothing short of astounding."
The photonics company has raised £12m in a Series A round led by Schlumberger to scale manufacturing of its greenhouse gas imaging technology.
"The technology is unique in the emissions monitoring marketplace in its potential to achieve the greatest amount of GHG abatement at the lowest cost of ownership,"
The seed round was led by Quantum Exponential Group and Evenlode Impact to support diagnostic imaging development.
"The closing of Siloton’s first round of investment represents a new chapter in the company’s history. We have a strong management team with world-leading technical know-how. This knowledge is complemented by the considerable expertise contained within our investor base; including clinical, sector, and commercial experts. We are all deeply excited to begin working together and building a compelling product for patients with age-related macular degeneration"